Alex Zhavoronkov, founder and CEO of Insilico Medicine, explores how artificial intelligence (A.I.) is driving breakthroughs in drug discovery and transforming the way medicines are discovered, tested, and delivered.
Zhavoronkov shares his vision for “pharma superintelligence,” a future where A.I. not only supports but also directs decision-making throughout the drug development process. This paradigm shift promises to accelerate innovation and improve outcomes across the pharmaceutical industry.
When paired with rigorous clinical validation, generative models in biomedicine have the potential to compress years of research into mere months, revolutionizing how quickly new treatments become available to patients.
https://observer.com/2025/09/interview-alex-zhavoronkov-insilico-drug-discovery-ai/